CA2299610A1 - Inhibiteurs selectifs du facteur xa - Google Patents

Inhibiteurs selectifs du facteur xa Download PDF

Info

Publication number
CA2299610A1
CA2299610A1 CA002299610A CA2299610A CA2299610A1 CA 2299610 A1 CA2299610 A1 CA 2299610A1 CA 002299610 A CA002299610 A CA 002299610A CA 2299610 A CA2299610 A CA 2299610A CA 2299610 A1 CA2299610 A1 CA 2299610A1
Authority
CA
Canada
Prior art keywords
group
6alkyl
compound
aryl
4alkylaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002299610A
Other languages
English (en)
Inventor
Robert M. Scarborough
Bing-Yan Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
COR Therapeutics Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2299610A1 publication Critical patent/CA2299610A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne de nouveaux composés, ainsi que leurs sels et leurs compositions, efficaces contre le facteur Xa mammalien. Ces composés, représentés par la formule (I), sont utiles in vitro et in vivo pour prévenir ou traiter les troubles de la coagulation.
CA002299610A 1997-08-11 1998-08-11 Inhibiteurs selectifs du facteur xa Abandoned CA2299610A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US8418497P 1997-08-11 1997-08-11
US90803197A 1997-08-11 1997-08-11
US60/084,184 1997-08-11
US08/908,031 1997-08-11
PCT/US1998/016705 WO1999007731A1 (fr) 1997-08-11 1998-08-11 INHIBITEURS SELECTIFS DU FACTEUR Xa

Publications (1)

Publication Number Publication Date
CA2299610A1 true CA2299610A1 (fr) 1999-02-18

Family

ID=26770690

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002299610A Abandoned CA2299610A1 (fr) 1997-08-11 1998-08-11 Inhibiteurs selectifs du facteur xa

Country Status (5)

Country Link
EP (1) EP0994894A1 (fr)
JP (1) JP2001515842A (fr)
CA (1) CA2299610A1 (fr)
NZ (1) NZ502876A (fr)
WO (1) WO1999007731A1 (fr)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6194435B1 (en) 1996-10-11 2001-02-27 Cor Therapeutics, Inc. Lactams as selective factor Xa inhibitors
US6063794A (en) 1996-10-11 2000-05-16 Cor Therapeutics Inc. Selective factor Xa inhibitors
US6369080B2 (en) 1996-10-11 2002-04-09 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6262047B1 (en) 1996-10-11 2001-07-17 Cor Therapeutics, Inc. Selective factor Xa inhibitors
JP2001521524A (ja) * 1997-04-14 2001-11-06 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
EP0975625A1 (fr) 1997-04-14 2000-02-02 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
JP2001523226A (ja) 1997-04-14 2001-11-20 シーオーアール セラピューティクス インコーポレイテッド 選択的Ｘａ因子阻害剤
WO1998046627A1 (fr) 1997-04-14 1998-10-22 Cor Therapeutics, Inc. INHIBITEURS SELECTIFS DU FACTEUR Xa
US6333321B1 (en) 1997-08-11 2001-12-25 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6228854B1 (en) 1997-08-11 2001-05-08 Cor Therapeutics, Inc. Selective factor Xa inhibitors
US6218382B1 (en) 1997-08-11 2001-04-17 Cor Therapeutics, Inc Selective factor Xa inhibitors
WO2000038618A2 (fr) 1998-12-24 2000-07-06 Du Pont Pharmaceuticals Company BENZODIAZEPINES SUCCINOYLAMINO UTILISEES COMME INHIBITEURS DE LA PRODUCTION DE PROTEINE A$g(b)
EP1156803A4 (fr) 1999-02-09 2004-03-17 Bristol Myers Squibb Co Inhibiteurs lactame de fxa et methode
MXPA02002657A (es) 1999-09-13 2002-10-28 Dimensional Pharm Inc Inhibidores de azacicloalcanona serina proteasa.
US6503902B2 (en) 1999-09-13 2003-01-07 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of a β protein production
US6960576B2 (en) 1999-09-13 2005-11-01 Bristol-Myers Squibb Pharma Company Hydroxyalkanoylaminolactams and related structures as inhibitors of Aβ protein production
CA2387493A1 (fr) 1999-10-08 2001-04-19 Lorin Andrew Thompson Amino sulfonamides de lactame utilises comme inhibiteurs de la production de proteine a.beta.
WO2001060826A2 (fr) 2000-02-17 2001-08-23 Bristol-Myers Squibb Pharma Company CARBOCYCLES ET HETEROCYCLES SUCCINOYLAMINO UTILISES EN TANT QU'INHIBITEURS DE LA PRODUCTION DE LA PROTEINE A$g(b)
US6495540B2 (en) 2000-03-28 2002-12-17 Bristol - Myers Squibb Pharma Company Lactams as inhibitors of A-β protein production
MXPA02009729A (es) 2000-04-03 2003-03-27 Bristol Myers Squibb Pharma Co Lactamas ciclicas como inhibidores de la produccion de la proteina a-beta.
BR0107532A (pt) 2000-04-03 2004-11-03 Bristol Myers Squibb Pharma Co Composto, uso do composto, método para o tratamento de disfunções neurológicas associadas com a produção de b-amilóide, método de inibição da atividade de y-secretase e composição farmacêutica
AU2001257006A1 (en) 2000-04-11 2001-10-23 Du Pont Pharmaceuticals Company Substituted lactams as inhibitors of abeta protein production
AU2001255408A1 (en) * 2000-04-14 2001-10-30 Corvas International, Inc. Tetrahydro-azepinone derivatives as thrombin inhibitors
BR0106717A (pt) 2000-06-01 2002-04-16 Bristol Myers Squibb Pharma Co Compostos, composição farmacêutica e usos dos compostos de lactama inovadora
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
US7479502B2 (en) 2002-12-03 2009-01-20 Pharmacyclics, Inc. 2-(2-hydroxybiphenyl-3-yl)-1H-benzoimidazole-5-carboxamidine derivatives as factor VIIA inhibitors
WO2005011611A2 (fr) * 2003-07-31 2005-02-10 Irm, Llc Composes bicycliques et compositions utilisees comme inhibiteurs pdf
CN109071504B (zh) 2016-02-05 2022-03-08 戴纳立制药公司 受体相互作用蛋白激酶1的抑制剂
DK3552017T3 (da) 2016-12-09 2022-05-16 Denali Therapeutics Inc Forbindelser, der er anvendelige som ripk1-inhibitorer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1995035311A1 (fr) * 1994-06-17 1995-12-28 Corvas International, Inc. Derives de l'acide 3-amino-2-oxo-1-piperidineacetique
CA2208773A1 (fr) * 1994-12-22 1996-06-27 John Dimaio Peptides de cetoarginine heterocycliques utilises comme inhibiteurs de thrombine
CA2268281A1 (fr) * 1996-10-11 1998-04-23 Cor Therapeutics, Inc. Inhibiteurs competitifs du facteur xa

Also Published As

Publication number Publication date
NZ502876A (en) 2001-11-30
EP0994894A1 (fr) 2000-04-26
WO1999007731A1 (fr) 1999-02-18
JP2001515842A (ja) 2001-09-25

Similar Documents

Publication Publication Date Title
CA2299610A1 (fr) Inhibiteurs selectifs du facteur xa
CA2268381A1 (fr) Inhibiteurs selectifs du facteur xa
CA2300478A1 (fr) Inhibiteurs selectifs du facteur xa
US6204268B1 (en) Selective factor Xa inhibitors
CA2268264A1 (fr) Inhibiteurs selectifs du facteur xa
EP0994893B1 (fr) INHIBITEURS SELECTIFS DU FACTEUR Xa CONTENANT UNE STRUCTURE D'AZEPINONE CONDENSEE
AU741099B2 (en) Selective factor Xa inhibitors
US6262047B1 (en) Selective factor Xa inhibitors
US6369063B1 (en) Selective factor Xa inhibitors
US6228854B1 (en) Selective factor Xa inhibitors
US6525076B1 (en) Selective factor Xa inhibitors
US6333321B1 (en) Selective factor Xa inhibitors
US6369080B2 (en) Selective factor Xa inhibitors
US6194435B1 (en) Lactams as selective factor Xa inhibitors
WO1998016524A1 (fr) DERIVES HETEROCYCLIQUES UTILISES COMME INHIBITEURS DE FACTEUR Xa
AU744626B2 (en) Selective factor Xa inhibitors
US6218382B1 (en) Selective factor Xa inhibitors
AU746471B2 (en) Selective factor Xa inhibitors containing a fused azepinone structure
AU743614B2 (en) Heterocyclic derivatives as factor Xa inhibitors
AU746596B2 (en) Selective factor Xa inhibitors
MXPA00001445A (en) SELECTIVE FACTOR Xa INHIBITORS
MXPA00001568A (en) SELECTIVE FACTOR Xa INHIBITORS CONTAINING A FUSED AZEPINONE STRUCTURE
AU8700598A (en) Selective factor xa inhibitors
MXPA00001443A (en) SELECTIVE FACTOR Xa INHIBITORS
AU9713401A (en) Heterocyclic derivatives as factor Xa inhibitors

Legal Events

Date Code Title Description
FZDE Dead